Literature DB >> 8584041

[3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study.

C Waeber1, M A Moskowitz.   

Abstract

We have used in vitro autoradiography to visualize [3H]sumatriptan binding sites in sections of guinea-pig and rat brain. In saturation studies, this ligand recognized a single saturable population of high affinity binding sites in all regions examined (pKD = 8.3-9.3). While 5-HT and the sumatriptan derivative CP-122,288 (5-methyl-aminosulfonylmethyl-3-(N-methylpyrrolidin-2R-yl-me thyl)- 1 H-indole) competed for [3H]sumatriptan binding sites with a high affinity and monophasic profile, displacement experiments with 5-carboxamidotryptamine revealed the existence of 2 classes of binding sites. The high affinity component (pKD = 9.2-9.9) probably corresponded to 5-HT1B (rat) or 5-HT1D (guinea-pig) receptors. The intermediate affinity (pKD = 5.7-7.3) of the other component, taken together with their high affinity for [3H]sumatriptan, was similar to that of the cloned 5-HT1F receptor. The regional distribution of the 5-HT1B/1D [3H]sumatriptan binding sites was in agreement with previously published studies (striatonigral system, hypothalamus, central gray, superficial layer of the superior colliculus) and corresponded to the pattern of serotonin-5-O-carboxymethyl-glycyl [125I]tyrosinamide labeling in consecutive sections. [3H]sumatriptan binding sites with a low affinity for 5-CT predominated in the intermediate neocortical layers, the claustrum (in the guinea-pig only), the mammillary nuclei, most of the thalamic nuclei and the principal oculomotor nucleus (in the guinea-pig only). This distribution is very similar to that of 5-HT1F mRNA, indicating further the identity of these sites with 5-HT1F receptors. Very high densities of 5-HT1F sites were also found in the rat parafascicular nucleus. Some regions, such as the caudate/nucleus, the lateral geniculate nuclei and the spinal trigeminal nucleus appeared to contain both 5-HT1B/1D and 5-HT1F binding sites. Ketanserin had a low affinity for [3H]sumatriptan binding sites in all guinea-pig brain regions, compatible with the presence of the 5-HT1D beta subtype. An exception was the substantia nigra, where a significant proportion of sites displayed an intermediate affinity for this compound, suggesting the presence of 5-HT1D chi receptors. [3H]5-HT labeled 5-HT1F sites in the claustrum and intermediate cortical layers in the guinea-pig. However these data show that [3H]sumatriptan, in the presence of 10 nM 5-carboxamidotryptamine, is a more suitable radioligand to study the distribution of 5-HT1F binding sites.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8584041     DOI: 10.1007/bf00168556

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  52 in total

Review 1.  A subfamily of 5-HT1D receptor genes.

Authors:  P R Hartig; T A Branchek; R L Weinshank
Journal:  Trends Pharmacol Sci       Date:  1992-04       Impact factor: 14.819

2.  Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype.

Authors:  G McAllister; A Charlesworth; C Snodin; M S Beer; A J Noble; D N Middlemiss; L L Iversen; P Whiting
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

3.  Distinct 5-HT(1B) and 5-HT(1D) serotonin receptors in rat: Structural and pharmacological comparison of the two cloned receptors.

Authors:  M W Hamblin; R W McGuffin; M A Metcalf; D M Dorsa; K M Merchant
Journal:  Mol Cell Neurosci       Date:  1992-12       Impact factor: 4.314

4.  Structure functional expression and spatial distribution of a cloned cDNA encoding a rat 5-HT1D-like receptor.

Authors:  A W Bach; L Unger; R Sprengel; G Mengod; J Palacios; P H Seeburg; M M Voigt
Journal:  J Recept Res       Date:  1993

5.  5.HT1 receptors in the vertebrate brain. Regional distribution examined by autoradiography.

Authors:  C Waeber; M M Dietl; D Hoyer; J M Palacios
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-11       Impact factor: 3.000

6.  Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries.

Authors:  E Hamel; E Fan; D Linville; V Ting; J G Villemure; L S Chia
Journal:  Mol Pharmacol       Date:  1993-08       Impact factor: 4.436

7.  Isolation of a mouse "5HT1E-like" serotonin receptor expressed predominantly in hippocampus.

Authors:  N Amlaiky; S Ramboz; U Boschert; J L Plassat; R Hen
Journal:  J Biol Chem       Date:  1992-10-05       Impact factor: 5.157

Review 8.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Authors:  D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

9.  The distribution of 5-HT1D and 5-HT1E binding sites in human brain.

Authors:  S Lowther; F De Paermentier; M R Crompton; R W Horton
Journal:  Eur J Pharmacol       Date:  1992-11-03       Impact factor: 4.432

10.  Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine.

Authors:  A Doenicke; J Brand; V L Perrin
Journal:  Lancet       Date:  1988-06-11       Impact factor: 79.321

View more
  19 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

Review 2.  The external globus pallidus: progress and perspectives.

Authors:  Daniel J Hegeman; Ellie S Hong; Vivian M Hernández; C Savio Chan
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

3.  [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain.

Authors:  Virginia L Lucaites; Joseph H Krushinski; John M Schaus; James E Audia; David L Nelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04-27       Impact factor: 3.000

Review 4.  Where does a migraine attack originate? In the brainstem.

Authors:  J Tajti; D Szok; Á Párdutz; B Tuka; A Csáti; A Kuris; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-03-18       Impact factor: 3.575

Review 5.  5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

Authors:  Lars Neeb; Jannis Meents; Uwe Reuter
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

6.  5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors.

Authors:  G Mengod; M T Vilaró; A Raurich; J F López-Giménez; R Cortés; J M Palacios
Journal:  Histochem J       Date:  1996-11

7.  Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.

Authors:  E Muñoz-Islas; S Gupta; L R Jiménez-Mena; J Lozano-Cuenca; A Sánchez-López; D Centurión; S Mehrotra; A MaassenVanDenBrink; C M Villalón
Journal:  Br J Pharmacol       Date:  2006-07-31       Impact factor: 8.739

8.  [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.

Authors:  David B Wainscott; Joseph H Krushinski; James E Audia; John M Schaus; John M Zgombick; Virginia L Lucaites; David L Nelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04-27       Impact factor: 3.000

9.  Bi-directional modulation of bed nucleus of stria terminalis neurons by 5-HT: molecular expression and functional properties of excitatory 5-HT receptor subtypes.

Authors:  J-D Guo; S E Hammack; R Hazra; L Levita; D G Rainnie
Journal:  Neuroscience       Date:  2009-09-22       Impact factor: 3.590

10.  Serotonin receptors are involved in the spinal mediation of descending facilitation of surgical incision-induced increase of Fos-like immunoreactivity in rats.

Authors:  João Walter S Silveira; Quintino M Dias; Elaine A Del Bel; Wiliam A Prado
Journal:  Mol Pain       Date:  2010-03-23       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.